2020 China Biotech Financing Top 10

In 2020, the capital market of the domestic biomedical sector will remain highly active.

Source: PharmaInvest

As a large number of celebrities or high-quality pharmaceutical companies achieve IPOs, it is the common appeal of investors to find the next high-quality potential target.

According to the PharmaInvest database, there will be a total of 1,660 financing incidents in the domestic medical and health sector in 2020, and 720 information publicly disclosed (excluding IPO/M&A/additional issuance), and the average amount of financing disclosed is nearly 40 million U.

NO.

Financing amount: 310 million US dollars

Financing time: 2020/10/29

Round: Pre-IPO

Investment institutions: RA Capital; Venrock Healthcare Capital Partners; SDIC Investment; BlackRock Assets; Casdin Capital; Farallon; Logos Capital; Perceptive Advisors; Pfizer; Sphera Healthcare; T.

Established on August 11, 2020, Liantuo Bio is an innovative drug company specially created and incubated by Perceptive Advisors, an American biomedical investment fund, in order to enter the Chinese market.

The team of Liantuo Bio is composed of senior people with rich local and cross-border work experience in China.

The slogan of Liantuo Bio is “Take science as the source and tap global innovative resources”.

On the day the company announced its establishment, Liantuo Biotech also announced a major project introduction transaction, cooperating with BridgeBio Pharma to introduce phase III selective FGFR inhibitor infigratinib and SHP2 inhibitor BBP-398.

On the same day, Liantuo Biotech also announced that it has reached a strategic cooperation with MyoKardia to introduce the development and commercialization rights of the innovative cardiomyopathy targeted therapy mavacamten in China and other Asian regions.

In the respiratory field, Liantuo Biotech reached a cooperation with ReViral on March 2, 2021 to introduce Sisunatovir, an innovative antiviral therapy for respiratory syncytial virus (RSV) infection, in the joint development and development of Sisunatovir in Mainland China, Hong Kong, Macau and Singapore.

NO.

Financing amount: 1 billion yuan (141 million US dollars)

Financing time: 2020/9/28

Round: D round

Investment institutions: Hillhouse Ventures; Qiming Ventures; Jianchao Industrial; AIHC Capital; Jingwei China; Deyi Capital; E Fund Capital; Eli Lilly Asia Fund; Aobo Capital; Pudong Science and Technology; Shanghui Capital; CMB International

Yifang Biological was established in 2013, co-founded by Dr.

At the beginning of its establishment, Yifang Biotechnology obtained angel investment from Beauty Realm Capital.

Yifang Bio focuses on lung cancer, breast cancer and gout and other diseases, and 4 innovative targeted small molecule drugs have entered clinical research.

NO.
3 Chuangsheng Group

Financing amount: US$100 million

Financing time: 2020/1/8

Round: B+ round

Investment institutions: Tengyue Fund; China Merchants Capital; China Resources Zhengda Life Science Fund; Eli Lilly Asia Fund; Sequoia Capital China; Temasek Holdings; Fortune Venture Capital; Xinzhongli Capital; Yipu Capital; Hillhouse Capital; ARCH Venture Partners

Chuangsheng Group was established in January 2019 by the merger of the two Bioteche companies, Yian Jishi Biopharmaceuticals and Maibos Biopharmaceuticals, integrating the respective advantages and talent teams of the two companies in drug discovery, development and production.
In 2020 On January 8th, it announced the completion of a $100 million B+ round of financing.

The product pipeline of Chuangsheng Group is mainly based on the foundation of the project before the company’s merger and establishment.
There are currently 9 new drug molecules involved in tumor, orthopedics and nephropathy.
The fastest development progress is the PD-L1 antibody MSB2311.
Proceed to Phase II.
In addition, the humanized Claudin 18.
2 monoclonal antibody TST001 for solid tumors is undergoing a phase I study in both China and the United States; the second-generation immunotherapy PDL1-TGFβ bispecific molecule TST005 for solid tumors is also in China and the United States.
Obtained clinical trial license.

Trauson Group signed an agreement with Eli Lilly in March 2019 to obtain the latter's exclusive development authorization for the entire Orthopedic innovative biopharmaceutical product line in Greater China, including the anti-sclerostin antibody TST002 (Blosozumab), which has completed the Phase II study in the United States.
Sclerostin is a negative regulator of bone formation.
Blocking the action of sclerostin can promote bone formation without increasing bone resorption.
The results of the Phase I human trial showed that Blosozumab has good safety and increased biomarkers of bone formation in subjects, suggesting that Blosozumab is a highly effective potential therapy for patients with severe osteoporosis who are at high risk of fractures.

After completing a $105 million cross-round financing in December 2020, Chuangsheng Group formally submitted hearing materials to the Hong Kong Stock Exchange on April 1, which is one step closer to listing on the Hong Kong Stock Exchange.

NO.
4 Conrad

Financing amount: 115 million US dollars

Financing time: 2020/8/24

Round: C round

Investment institutions: RA Capital; Eli Lilly Asia Fund; Boxer Capital; HBM Healthcare Investments; Qiming Venture Capital

Conrad was established in 2012 and is committed to developing innovative therapies through its self-developed T cell function regulation platform to improve the quality of life of patients with inflammatory immune diseases.
The company's co-founder, Dr.
Wei Zheng, has more than 25 years of experience in the treatment of autoimmune diseases and inflammation, and Dr.
Wubin Pan has more than 25 years of experience in the field of biopharmaceutical research and development.

Since its establishment, Conrad has completed multiple rounds of financing.
In August 2020, it completed the largest US$115 million Series C financing before the listing.
Investment institutions include RA Capital, Eli Lilly Asia Fund, Boxer Capital, HBM Healthcare Investments, Qiming Chuang cast.
Conrad has officially listed on the Nasdaq IPO on March 19 this year.
The IPO issued 11.
25 million American Depositary Shares (ADS), priced at US$17 per share, and the total amount of funds raised was approximately US$191 million.

Conrad has established a high-throughput drug screening platform based on T cell immune regulation.
Compared with traditional methods, this platform can quickly and efficiently identify and screen disease therapeutic molecules against related targets.
In terms of product pipeline, Conrad currently mainly promotes 4 products, including CBP-201, CBP-307, CBP-174 and CBP-233.

CBP-201 is an antibody (Th2 cell regulator) targeting IL-4Ra.
It has now entered Phase II clinical development.
The proposed indications include atopic dermatitis, asthma and chronic sinusitis with nasal polyps.
Conrad defines CBP-201 as a potential Best-in-Class drug.
Ib clinical research data show that CBP-201 can quickly improve the skin lesions of patients with moderate to severe atopic dermatitis, and has good safety and tolerability.

CBP-307 is a small molecule (Th1 cell modulator) targeting S1P1 and is currently undergoing phase II clinical trials in patients with ulcerative colitis and Crohn's disease.
CBP-174 is a peripherally restricted H3 receptor antagonist.
The proposed indication is AD-related pruritus.
It has entered phase I clinical trials.
CBP-233 is an antibody that targets IL-33.
The proposed indication is allergic inflammation.
The project is currently in the pre-clinical development stage.

Conrad can be called the "darling" of capital, in addition to its product advantages, it is also related to the huge market for autoimmune diseases.
According to statistics, by 2030, the domestic autoimmune disease market will exceed 100 billion yuan.

NO.
5 Ruike Biology

Financing amount: over 100 million US dollars

Financing time: 2020/11/10

Round: B round

Investment institutions: Legend Capital; Jifeng Capital; Sequoia Capital; Temasek Xiangfeng; Haitong Kaiyuan; Cornerstone Capital; Yuansheng Venture Capital; Qingsong Capital; Everbright Holdings; Oriental Fortune; Shenzhen Woying Investment; Ningbo Haojin Zhitong

Ruike Biology was established as early as May 2012.
In January 2019, it merged with Beijing Anbaisheng Biological Technology Co.
, Ltd.
to form the current Ruike Biology.
Liu Yong, the founder and general manager of Ruike Biotechnology, is mainly engaged in the research and development of new vaccines for major diseases.
He is the review expert of the Ministry of Science and Technology of the National "Major New Drug Creation" Science and Technology Project.
He has served as the deputy head of the DNA vaccine of the NIH CIPRA project in the United States.
The person in charge of the AIDS DNA vaccine sub-project of the major scientific and technological project of "viral hepatitis and other major infectious diseases".
He has published more than 30 research papers in SCI and above core journals, declared more than 20 invention patents, and has authorized 10 items.

Ruike Biotechnology completed 500 million yuan in Series A financing on January 25, 2019, and over 100 million US dollars in Series B financing on November 10, 2020.
It was funded by Legend Capital, Jifeng Capital, Sequoia Capital China Fund, and Xiang Feng Investment, Haitong Kaiyuan, Cornerstone Capital, Yuansheng Venture Capital, Qingsong Capital, Everbright Holdings and other well-known venture capital institutions at home and abroad jointly invested.
This financing focuses on the company's key product industrialization base construction, HPV nine-valent vaccine, recombinant new crown vaccine and other product clinical trials, follow-up product pipeline research and development, core technology platform construction and international expansion.

Reco Bio focuses on vaccine development.
After 9 years of development, it has established a leading domestic R&D and innovation platform such as new adjuvants, genetic engineering, and immune evaluation.
Currently, there are HPV series vaccines, recombinant herpes zoster virus vaccines, tuberculosis vaccines, and recombinant vaccines.
Many product lines with a market capacity of tens of billions, represented by the new crown vaccine, are in different stages of development.
Ruike Biotechnology is stepping up the construction of HPV vaccine and new crown vaccine industrialization base.
The annual output of nine-valent HPV cervical cancer vaccine will reach 5 million, and the annual output value is expected to exceed 4 billion yuan.
At the same time, Ruike Biotech is also actively deploying international business.

NO.
6 endowment organisms

Financing amount: 150 million US dollars

Financing time: 2020/8/18

Round: A round

Investment institutions: Eli Lilly Asia Fund; F-Prime; Stow Capital; Sequoia Capital; Hillhouse Capital; ARCH Venture Partners

Fuyuan Biology is also a company incubated by capital institutions.
It was established in 2019.
There is not much information about company introductions that can be publicly searched on the Internet.
On August 18, 2020, it was reported that Fuyuan Biotechnology completed a US$150 million Series A financing.
Investors include Stauward Capital, F-Prime Capital, Eli Lilly Asia Fund, Hillhouse Capital, Sequoia Capital and ARCHVenture and other top institutions.

Fuyuan Bio focuses on the world's cutting-edge gene and cell therapy fields, and promotes the development and listing of new drugs for rare diseases and cancer treatment fields to meet the needs of patients.
The Fuyuan R&D Center is located in Zhangjiang, Shanghai.
It has been officially opened with a total area of ​​6,000 square meters.
It has established a complete gene and cell therapy R&D platform, including the construction and production of viral vectors, and large-scale cell and virus production process development.
, And downstream purification platform.
It can accommodate more than 200 scientists for project research.

NO.
7 Saishen Medicine

Financing amount: US$100 million

Financing time: 2020/12/8

Round: A round

Investment institutions: Eli Lilly Asia Fund; Sequoia Capital China; Boyu Capital; Pan Atlantic Investment; Taifu Capital; All Things Capital; ARCH Venture Partners

Established in January 2020, Saishen Medicine is an innovative drug company focused on neurological disease business incubated by capital institutions.
Saishen Medicine is a relatively new company.
On December 8, 2020, it announced the completion of US$100 million in Series A financing.
It was jointly led by Eli Lilly Asia Fund and Arch Venture Partners, Boyu Capital, General Atlantic, Sequoia Capital China, and Taifu Capital and Zoo Capital will join in the investment.
The financing is mainly used to establish and develop the CNS product portfolio.
The initial business will focus on the Greater China region.

One in six people in China suffers from central nervous system diseases.
CNS diseases not only affect patients, but also affect their families and society.
However, there are relatively few effective methods for treating CNS diseases and the development is extremely difficult.
Saishen Medicine will meet this clinical need by establishing a CNS innovative product portfolio.

Dr.
Limin, the CEO of Saishen Medicine, is one of Eli Lilly's Asia Venture Capital Partners.
He was the Vice President of Neuroscience R&D at GSK.
Prior to GSK, he was a tenured professor of neuroscience at Johns Hopkins University School of Medicine.
Chief Medical Officer Dr.
Ang Qiuqing has 10 years of clinical experience in the treatment of CNS diseases in China, and has held CNS clinical development leadership positions for Eli Lilly, Pfizer and GlaxoSmithKline for more than 15 years.
She also served as the chief scientific officer of Kelun Pharmaceutical before, and has led a number of clinical development projects in China and around the world from application to successful approval.
Senior Vice President and Head of Translational Science, Dr.
Danny Chen is the former executive director of Pfizer (USA) Neuroscience R&D Department; he has led many first human experiments and early clinical development projects in the field of CNS diseases.
Chief Commercial Officer Dr.
Paul Stead has more than 15 years of experience in leading business development and business transactions for biotechnology companies and large pharmaceutical companies (GSK).

It can be seen that the senior management team of Saishen Medicine has a background in industrial research and development, academic research, clinical diagnosis and treatment and business development in the field of neurological diseases.
Their strengths complement each other and appear to be more powerful.
This will help Saishen Medicine to quickly screen and build a competitive The powerful neurological disease product line can bring innovative solutions that can meet the huge clinical needs of patients in China and even around the world.
Saishen Pharmaceutical’s current product pipeline has not been disclosed.
After the funds are in place, its subsequent product layout actions are worthy of attention.

NO.
8 Liberal Arts Collection

Financing amount: 450 million yuan (63.
36 million US dollars)

Financing time: 2020/10/13

Round: B round

Investment institutions: IDG Capital; Eli Lilly Asia Fund; Sequoia Capital China; Sanzheng Health Investment; Kunlun Capital; Yahui Investment; Huagai Capital; Songhe Capital

Boya Jiyin was established in 2015 by Professor Wei Wensheng from the School of Life Sciences, Peking University.
Wei Wensheng’s laboratory was engaged in basic research on bacteria and pathogens in the early years, during which it used the earliest gene editing technologies such as ZFN (zinc finger nuclease) and TALEN (transcription activator-like effector nuclease).
After the emergence of CRISPR gene editing technology, as one of the first domestic introducers, his laboratory published the results of CRISPR as a high-throughput genome editing and screening new drug research and development platform in Nature in 2014.
Since then, laboratory gene editing technology has developed rapidly, and is currently in an international leading position in the field of gene editing.

CEO“”，20，BioMarin、Elan、、（），、、、、。

7，2020104.
5B，IDG、、、、、、、。

，，，：1）T；2）RNA；3）。

ET-01β、CRISPR/Cas9，CRISPR/Cas9BCL11ACD34+。20211，ET-01，。，30，β。

NO.
9

：7000

：2020/3/25

：C

：; ; ; GIC; ; ;

20164，、、。，（），，、。，、、，。

。2016、，441.
4（7500C），202111.
23D。

，，4，7IND，10。

，，，FGFR4，20％FGFR19 / FGFR4，，FGFR4ABSK011，pan-FGFRABSK091（AZD4547）。

，，PD-L1ABSK043，CSF-1RABSK021。ABSK021，CSF-1RT，I/O。

NO.
10

：

：2020/8/26

：A

：; ; ; ; ;

20186，、first in class，CEO，、、，30。

5，、、、，AGA111，I/II。（、、），，。，。AGA111，，，，。

、，，。，，。

20209，、、、、、A，。